SPC
RNTX

Sigma Planning Corp’s Rein Therapeutics RNTX Stock Holding History

Sigma Planning Corp’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Buy
353,677
+5,000
+1% +$6.05K 0.01% 1047
2026
Q1 		$453K Buy
348,677
+101,400
+41% +$126K 0.01% 877
2025
Q4 		$299K Sell
247,277
-6,550
-3% -$9.03K 0.01% 1027
2025
Q3 		$291K Sell
253,827
-22,950
-8% -$29.1K 0.01% 1042
2025
Q2 		$387K Sell
276,777
-28,398
-9% -$51.1K 0.01% 882
2025
Q1 		$540K Buy
305,175
+68,965
+29% +$145K 0.02% 701
2024
Q4 		$543K Buy
236,210
+23,800
+11% +$72.1K 0.02% 711
2024
Q3 		$752K Buy
212,410
+86,185
+68% +$230K 0.02% 592
2024
Q2 		$350K Buy
126,225
+58,240
+86% +$239K 0.01% 860
2024
Q1 		$451K Buy
67,985
+51,405
+310% +$246K 0.01% 801
2023
Q4 		$50.5K Buy
+16,580
New +$32.3K ﹤0.01% 829

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Sigma Planning Corp's RNTX Position: Q2 2026 in Review

Sigma Planning Corp increased its Rein Therapeutics (RNTX) stake by 1.4% in Q2 2026, buying an estimated $6.05K and bringing the position to 353,677 shares worth $368K. The position accounts for 0.01% of the portfolio, ranked #1047.

Sigma Planning Corp first reported a position in RNTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $752K in Q3 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Sigma Planning Corp held 353,677 shares of Rein Therapeutics worth $368K as of Q2 2026.
  • Sigma Planning Corp bought 5,000 Rein Therapeutics shares in Q2 2026, an estimated $6.05K.
  • Rein Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #1047 holding.
  • Sigma Planning Corp first reported a position in Rein Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Sigma Planning Corp's Rein Therapeutics position peaked at $752K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.